107 results on '"Chouaïd C"'
Search Results
2. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
3. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
4. Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis
5. Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study
6. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
7. Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors
8. Deux cas d’hyperprogressions de mésothéliomes pleuraux sous inhibiteurs des checkpoints
9. Explore ALK : Alectinib chez les patients atteints de cancer du poumon non à petites cellules métastatique ALK+: une analyse nationale en vie réelle (GFPC 03-2019)
10. Impact of the COVID-19 pandemic on COPD patients: a nationwide mortality study in France
11. Artificial intelligence to finally enable precision medicine for the management of resected non-small cell lung cancer
12. 76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis
13. 121P Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
14. Patients en vie 5 ans après l’initiation de nivolumab dans le cancer bronchique non à petites cellules métastatique : caractéristiques, prise en charge et consommations de soins
15. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study
16. 1806P Clinical characteristics and management of small cell lung cancer long survivors
17. 1368P Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial
18. 1286P Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients
19. 1249P Health-related quality of life (HRQoL) at diagnosis for unresectable stage III NSCLC: Results from the French nationwide prospective study OBSTINATE (GFPC 06-2019)
20. Utilisation de la nouvelle cartographie d'impact organisationnel publiée par la Haute Autorité de santé (HAS) pour évaluer l'impact organisationnel (IO) des immunothérapies dans les cancers avancés
21. Efficacité du Pembrolizumab en première ligne de prise en charge de cancers du poumon non à petites cellules métastatiques, PDL1 ≥ 50 % avec métastases cérébrales (étude ESCKEYP – GFPC 05–2018)
22. EE520 Hospital Costs in Resected Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC): A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)
23. EE64 Change in Healthcare Resource Use and Associated Costs of Patients with Metastatic Lung Cancer between 2013 and 2019: An Observational Study from the French National Claims Database
24. SIOG2023-4-P-275 - Predicting moderate and severe chemotherapy toxicity in older patients with cancer
25. LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
26. 1417P Change in healthcare resource use and associated costs of patients with metastatic lung cancer between 2013 and 2019: An observational study from the French national claims database
27. 1401P Impact of KRAS mutation on non-small cell lung cancer survival outcomes
28. 1369P BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
29. 2182P Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
30. 2179P Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
31. 56P Pooled analysis of 4 studies evaluating weekly oral vinorelbine in patients with locally advanced or metastatic non-small cell lung cancer
32. Résultats intermédiaires sur les 658 premiers patients de l’étude PRAISE (Patient-Reported AutoImmunity SEcondary to cancer immunotherapy) : étude de cohorte prospective multicentrique pour le suivi des manifestations auto-immunes sous immunothérapie
33. EE324 Cost-Effectiveness analysis of Atezolizumab as Adjuvant Treatment of Patients With Stage II-IIIA Non-Small Cell Lung Cancer, With Pd-L1≥50% of Tumor Cells, in France
34. CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
35. 1605P Comparison of the prognostic value of comorbidities in older patients with colorectal, breast, prostate or lung cancer: The ELCAPA cohort study
36. 1330P Organizational impact of immune-checkpoint inhibitors in advanced cancers in France: Final analysis
37. 1180P Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice
38. 1154P Geriatrics predictors of 3-months overall survival and chemotherapy toxicities in older patients with metastatic non-small cell lung cancer
39. 1122P An adjusted comparison of amivantamab phase II data versus real-world clinical management in France of EGFR exon 20 insertion-mutated (ex20ins) advanced NSCLC patients
40. 1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy
41. 1035P A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)
42. 1016P GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies
43. 962P Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019)
44. 937P Incidence and outcomes of EGFR mutated non-small cell lung cancer treated with surgery: EXERPOS GFPC study
45. PO-33: Real-world VTE and implemented treatments in patients with cancer: an observational study in the French EGB database
46. 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
47. BRIGAROS : évaluation du brigatinib en accès compassionnel chez les patients porteurs d’un cancer bronchique non à petites cellules avec réarrangement de ROS1
48. Étude de vraie vie d’utilisation du durvalumab en consolidation après radio-chimiothérapie dans les CBNPC de stade III non résécables : cohorte française de PACIFIC-R
49. Impact de la maladie thrombo-embolique chez les patients traités par Pembrolizumab en première ligne pour un cancer du poumon non à petites cellules, métastatique, PDL1 > 50%
50. Caractéristiques cliniques et qualité de vie au diagnostic des CBNPC de stade III non-opérables en pratique courante : essai OBSTINATE (GFPC 06–2019)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.